الفهرس 
Introduction and aim of work
Microscopic pictureOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
NHL is a malignant heterogeneous group of diseases with different clinical presentations, histologic subtypes, molecular features and suitable mode of treatment. So, the identification of ‘biological’ prognostic factors is therefore very important in NHL to define the risk groups in clinical trials.
The current study was done on 150 cases of NHL previously diagnosed at pathology laboratory of oncology center of Mansoura University from September 2009 to November 2011. Minimum follow up time was 24 months and maximum was 54 months. Paraffin blocks of excision lymph node biopsy were yield to immunohistochemical staining for both Ki67&BCL2.
The present study revealed that the BCL2 have the strongest impact on prognosis of NHL; increased its expression more than 42.5% indicated failure of complete remission, risk ratio for death about 2.3 times, increased potentiality of relapse 3 times and shorter median survival about 20 months only. When BCL2 expression increased more than 52.5% indicated PFS less than 1 year with risk ratio 2.5 times. The current study revealed statistically no significant correlation between IPI scores of NHL cases and BCL2 values. In NHL cases as general, the present study revealed that Ki67 PI has no strong impact on the prognosis of patients treated with chemotherapy alone. The current work reported no relation between Ki67 PI and the following prognostic parameters (rate of complete remission, risk for death, potentiality of relapse, PFS and OS). Also, there was no correlation between Ki67 and IPI.
The present study revealed limited value of Ki67 in aggressive NHL cases as DLBCL when combined only with BCL2 by using a cut-off 70% for Ki67 and 40% for BCL2.